Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

The appointment of Dr. Banerjee culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmunity and cell therapy that includes the following recent additions: ...

In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

While the biotech has yet to announce any clinical results for the antibody, Sanofi implied in a March 20 release that it’s pleased with the “robust” B-cell depletion it has seen so far.

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...